Supernus Pharmaceuticals SUPN
NASDAQ SUPN
$42.38 +0.20 (+0.47%)
At close: Oct 2, 2026 · 4:00 PM EDT

Supernus Pharmaceuticals (SUPN) Gains from Sales and Divestitures (2011)

Updated

Supernus Pharmaceuticals (SUPN) recorded Gains from Sales and Divestitures of $25,000 in FY2011, down 53.7% from $54,000 in FY2010.

Analysis

Supernus Pharmaceuticals (SUPN) Gains from Sales and Divestitures (2011) Analysis & Trends

  • Per Business Quant data, SUPN's Gains from Sales and Divestitures was $54,000 in FY2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Supernus Pharmaceuticals 2.47 Bn 1.12 Bn 185.39 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 -2,000.00
Jun 30, 2011 2,000.00
Mar 31, 2011 25,000.00
API Access

Supernus Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SUPN&period=max&api_key=YOUR_API_KEY